Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GELS declined for three days, in 117 of 124 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The 10-day RSI Indicator for GELS moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 5 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
GELS broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 18 of 22 cases where GELS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on September 01, 2026. You may want to consider a long position or call options on GELS as a result. In 28 of 33 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for GELS just turned positive on August 25, 2026. Looking at past instances where GELS's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.
GELS moved above its 50-day moving average on September 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GELS crossed bullishly above the 50-day moving average on September 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +28.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where GELS advanced for three days, in 47 of 59 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 10 of 10 cases where GELS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. GELS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.731) is normal, around the industry mean (46.728). P/E Ratio (0.000) is within average values for comparable stocks, (93.360). GELS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). GELS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (62.500) is also within normal values, averaging (176.516).
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GELS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric